Logo Logo
Switch Language to German
Sebio, A.; Matsusaka, S.; Zhang, W.; Yang, D.; Ning, Y.; Stremitzer, S.; Stintzing, S.; Sunakawa, Y.; Yamauchi, S.; Fujimoto, Y.; Ueno, M.; Lenz, H-J (2016): Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer. In: Pharmacogenomics Journal, Vol. 16, No. 4: pp. 312-319
Full text not available from 'Open Access LMU'.


The Hippo pathway regulates tissue growth and cell fate. In colon cancer, Hippo pathway deregulation promotes cellular quiescence and resistance to 5-Fluorouracil (5-Fu). In this study, 14 polymorphisms in 8 genes involved in the Hippo pathway (MST1, MST2, LATS1, LATS2, YAP, TAZ, FAT4 and RASSF1A) were evaluated as recurrence predictors in 194 patients with stages II/III colon cancer treated with 5-Fu-based adjuvant chemotherapy. Patients with a RASSF1A rs2236947 AA genotype had higher 3-year recurrence rate than patients with CA/CC genotypes (56 vs 33%, hazard ratio (HR): 1.87;P = 0.017). Patients with TAZ rs3811715 CT or TT genotypes had lower 3-year recurrence rate than patients with a CC genotype (28 vs 40%;HR: 0.66;P = 0.07). In left-sided tumors, this association was stronger (HR: 0.29;P = 0.011) and a similar trend was found in an independent Japanese cohort. These promising results reveal polymorphisms in the Hippo pathway as biomarkers for stages II and III colon cancer.